Log in

NYSE:ELAN - Elanco Animal Health Stock Price, Forecast & News

-0.68 (-2.11 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
Now: $31.57
50-Day Range
MA: $28.98
52-Week Range
Now: $31.57
Volume10.90 million shs
Average Volume6.80 million shs
Market Capitalization$11.78 billion
P/E Ratio121.43
Dividend YieldN/A
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$1.95 per share
Book Value$14.22 per share


Net Income$86.50 million


Market Cap$11.78 billion
Next Earnings Date2/19/2020 (Confirmed)

Receive ELAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.

Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions

What is Elanco Animal Health's stock symbol?

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Wednesday, November, 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.26 by $0.04. The business had revenue of $771.30 million for the quarter, compared to analyst estimates of $765.85 million. Elanco Animal Health had a net margin of 3.04% and a return on equity of 7.79%. The firm's revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. View Elanco Animal Health's Earnings History.

When is Elanco Animal Health's next earnings date?

Elanco Animal Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Elanco Animal Health.

How can I listen to Elanco Animal Health's earnings call?

Elanco Animal Health will be holding an earnings conference call on Wednesday, February 19th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health updated its FY20 earnings guidance on Friday, January, 10th. The company provided earnings per share (EPS) guidance of 1.09-1.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.22. The company issued revenue guidance of $3.05-3.11 billion, compared to the consensus revenue estimate of $3.13 billion.

What price target have analysts set for ELAN?

10 equities research analysts have issued twelve-month price targets for Elanco Animal Health's shares. Their forecasts range from $28.00 to $36.00. On average, they anticipate Elanco Animal Health's share price to reach $32.45 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price. View Analyst Price Targets for Elanco Animal Health.

What is the consensus analysts' recommendation for Elanco Animal Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Elanco Animal Health.

Has Elanco Animal Health been receiving favorable news coverage?

Media stories about ELAN stock have been trending extremely negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Elanco Animal Health earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Elanco Animal Health.

Are investors shorting Elanco Animal Health?

Elanco Animal Health saw a increase in short interest in December. As of December 31st, there was short interest totalling 13,470,000 shares, an increase of 11.2% from the December 15th total of 12,110,000 shares. Based on an average daily volume of 3,770,000 shares, the short-interest ratio is presently 3.6 days. Approximately 3.6% of the shares of the stock are short sold. View Elanco Animal Health's Current Options Chain.

Who are some of Elanco Animal Health's key competitors?

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), AT&T (T), Micron Technology (MU), Home Depot (HD), CVS Health (CVS), Walt Disney (DIS), AbbVie (ABBV), Pfizer (PFE) and Verizon Communications (VZ).

Who are Elanco Animal Health's key executives?

Elanco Animal Health's management team includes the folowing people:
  • Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 52)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 47)
  • Mr. David S. Kinard, Exec. VP of HR (Age 52)
  • Ms. Sarena S. Lin, Exec. VP of Elanco USA, Corp. Strategy & Global Marketing (Age 48)
  • Mr. David Alan Urbanek, Exec. VP of Manufacturing & Quality (Age 53)

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Global Thematic Partners LLC (0.34%), Nippon Life Global Investors Americas Inc. (0.10%), Artemis Investment Management LLP (0.08%), Heritage Investors Management Corp (0.05%), Three Peaks Capital Management LLC (0.05%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Institutional Ownership Trends for Elanco Animal Health.

Which major investors are selling Elanco Animal Health stock?

ELAN stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Zurcher Kantonalbank Zurich Cantonalbank , Janney Montgomery Scott LLC, Perennial Advisors LLC, State of Alaska Department of Revenue, Ingalls & Snyder LLC, BKD Wealth Advisors LLC and Diversified Trust Co. View Insider Buying and Selling for Elanco Animal Health.

Which major investors are buying Elanco Animal Health stock?

ELAN stock was acquired by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Artemis Investment Management LLP, Nisa Investment Advisors LLC, Nippon Life Global Investors Americas Inc., Three Peaks Capital Management LLC, DNB Asset Management AS, Telemus Capital LLC and SFE Investment Counsel. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Insider Buying and Selling for Elanco Animal Health.

How do I buy shares of Elanco Animal Health?

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Elanco Animal Health's stock price today?

One share of ELAN stock can currently be purchased for approximately $31.57.

How big of a company is Elanco Animal Health?

Elanco Animal Health has a market capitalization of $11.78 billion and generates $3.07 billion in revenue each year. The company earns $86.50 million in net income (profit) each year or $1.18 on an earnings per share basis. Elanco Animal Health employs 5,590 workers across the globe.View Additional Information About Elanco Animal Health.

What is Elanco Animal Health's official website?

The official website for Elanco Animal Health is http://www.elanco.com/.

How can I contact Elanco Animal Health?

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.

MarketBeat Community Rating for Elanco Animal Health (NYSE ELAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Elanco Animal Health and other stocks. Vote "Outperform" if you believe ELAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel